BR112018075901A2 - anticorpo humanizado ou fragmento de ligação a anticorpo, uso deste, complexo in vitro, opcionalmente isolado, e método in vitro - Google Patents
anticorpo humanizado ou fragmento de ligação a anticorpo, uso deste, complexo in vitro, opcionalmente isolado, e método in vitroInfo
- Publication number
- BR112018075901A2 BR112018075901A2 BR112018075901-5A BR112018075901A BR112018075901A2 BR 112018075901 A2 BR112018075901 A2 BR 112018075901A2 BR 112018075901 A BR112018075901 A BR 112018075901A BR 112018075901 A2 BR112018075901 A2 BR 112018075901A2
- Authority
- BR
- Brazil
- Prior art keywords
- vitro
- binding fragment
- antibody
- optionally isolated
- complex
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201604834P | 2016-06-14 | ||
| SG10201604834P | 2016-06-14 | ||
| PCT/SG2017/050300 WO2017217934A1 (en) | 2016-06-14 | 2017-06-14 | Prl3 antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018075901A2 true BR112018075901A2 (pt) | 2019-03-19 |
Family
ID=60663634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018075901-5A BR112018075901A2 (pt) | 2016-06-14 | 2017-06-14 | anticorpo humanizado ou fragmento de ligação a anticorpo, uso deste, complexo in vitro, opcionalmente isolado, e método in vitro |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11155636B2 (enExample) |
| EP (1) | EP3469003A4 (enExample) |
| JP (2) | JP2019531254A (enExample) |
| KR (1) | KR102451588B1 (enExample) |
| CN (1) | CN109476759B (enExample) |
| AU (1) | AU2017285995B2 (enExample) |
| BR (1) | BR112018075901A2 (enExample) |
| CA (1) | CA3025756A1 (enExample) |
| SG (1) | SG11201811068YA (enExample) |
| WO (1) | WO2017217934A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119110747A (zh) | 2022-05-11 | 2024-12-10 | 国立研究开发法人产业技术综合研究所 | 氨分离膜及使用了其的氨分离方法 |
| TW202532435A (zh) * | 2023-11-30 | 2025-08-16 | 新加坡科技研究局 | 治療新生血管性眼疾之方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050287644A1 (en) | 2004-05-14 | 2005-12-29 | Genesis Biotech Inc. | Methods for producing and culturing rabbit-mouse hybridomas and monoclonal antibodies secreted by rabbit-mouse hybridomas |
| US7462697B2 (en) * | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
| WO2006091326A1 (en) | 2005-01-28 | 2006-08-31 | Attogen Inc. | Anti-prl-3 antibodies and methods of use thereof |
| CN101820910B (zh) * | 2007-05-03 | 2014-08-06 | 新加坡科技研究局 | 结合细胞内prl-1多肽或prl-3多肽的抗体 |
| JP2012505654A (ja) * | 2008-10-14 | 2012-03-08 | ヤンセン バイオテツク，インコーポレーテツド | 抗体をヒト化及び親和性成熟する方法 |
| WO2011065923A1 (en) | 2009-11-30 | 2011-06-03 | Agency For Science, Technology And Research | Treatment and prevention of cancers associated with intracellular oncoproteins by antibody therapy or vaccination |
| WO2015119570A1 (en) * | 2014-02-07 | 2015-08-13 | Agency For Science, Technology And Research | Prl-3 as a biomarker for the prognosis of cancer and a target for therapy |
-
2017
- 2017-06-14 SG SG11201811068YA patent/SG11201811068YA/en unknown
- 2017-06-14 JP JP2018565319A patent/JP2019531254A/ja active Pending
- 2017-06-14 CN CN201780037479.8A patent/CN109476759B/zh active Active
- 2017-06-14 BR BR112018075901-5A patent/BR112018075901A2/pt not_active Application Discontinuation
- 2017-06-14 KR KR1020197001195A patent/KR102451588B1/ko active Active
- 2017-06-14 CA CA3025756A patent/CA3025756A1/en active Pending
- 2017-06-14 WO PCT/SG2017/050300 patent/WO2017217934A1/en not_active Ceased
- 2017-06-14 AU AU2017285995A patent/AU2017285995B2/en active Active
- 2017-06-14 US US16/309,439 patent/US11155636B2/en active Active
- 2017-06-14 EP EP17813707.1A patent/EP3469003A4/en active Pending
-
2022
- 2022-03-04 JP JP2022033194A patent/JP7408707B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3025756A1 (en) | 2017-12-21 |
| CN109476759B (zh) | 2022-11-08 |
| US11155636B2 (en) | 2021-10-26 |
| KR20190024961A (ko) | 2019-03-08 |
| JP2022078202A (ja) | 2022-05-24 |
| AU2017285995A1 (en) | 2019-01-31 |
| EP3469003A4 (en) | 2020-07-29 |
| US20200181283A1 (en) | 2020-06-11 |
| JP2019531254A (ja) | 2019-10-31 |
| EP3469003A1 (en) | 2019-04-17 |
| CN109476759A (zh) | 2019-03-15 |
| JP7408707B2 (ja) | 2024-01-05 |
| AU2017285995B2 (en) | 2023-11-30 |
| KR102451588B1 (ko) | 2022-10-06 |
| SG11201811068YA (en) | 2019-01-30 |
| WO2017217934A1 (en) | 2017-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024002250A1 (es) | Uso de anticuerpo anti-vd1 para tratar cáncer, una enfermedad infecciosa o una enfermedad inflamatoria. | |
| UY37928A (es) | Anticuerpos anti-cd38 y métodos de uso | |
| CL2023001064A1 (es) | Proteína de unión al antígeno anti-steap1 | |
| MX2021011696A (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123. | |
| BR112019000327A8 (pt) | Anticorpo para anticlaudina 18a2 e uso do mesmo | |
| BR112019002168A2 (pt) | anticorpos trivalentes bispecíficos ligantes a claudina6 ou claudina18.2 e cd3 para o tratamento de doenças cancerígenas que expressam claudina | |
| BR112019011186A2 (pt) | conjugado de anticorpo radiomarcado, composto, e, métodos de imageamento e para tratamento de um tumor. | |
| BR112018000768A2 (pt) | anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos | |
| JOP20190292A1 (ar) | استخدام الأجسام المضادة لربط il-1? في علاج السرطان | |
| MX2022011935A (es) | Terapeuticos de anticuerpo que se unen a ctla4. | |
| CO2018014325A2 (es) | Anticuerpos específicos para la tau hiperfosforilada y sus métodos de uso | |
| BR112017006468A2 (pt) | anticorpo biespecífico, composição farmacêutica, kit, uso de uma combinação de um anticorpo biespecífico e método de tratamento de câncer | |
| AR101846A1 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
| DOP2018000045A (es) | Anticuerpos pd-l1 | |
| BR112018002844A2 (pt) | receptores de antígeno quimérico à base de anticorpos de domínio único e métodos de uso dos mesmos | |
| BR112015022123A8 (pt) | Anticorpos, fragmentos de ligação ao antígeno dos mesmos que se ligam especificamente à hepcidina ou um peptídeo de hepcidina, uso, meio contentor e kit | |
| EA201890383A1 (ru) | Конструкции биспецифических антител, связывающиеся с мезотелином и кд3 (cd3) | |
| EA201890382A1 (ru) | Конструкции антител для cd70 и cd3 | |
| BR112016020752A2 (pt) | ?anticorpo isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, e, métodos para tratamento de um câncer ou tumor expressando egfrviii e para tratamento de um câncer, redução de crescimento de tumor e/ou causação de regressão de tumor em um paciente? | |
| BR112019000436A2 (pt) | anticorpos anti-pd-1, método de produção e método de uso dos mesmos | |
| BR112013021562A2 (pt) | anticorpos para cd70 | |
| BR112015007672A2 (pt) | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso | |
| BR112018072066A2 (pt) | moléculas de ligação específicas para fcgamariia e uso das mesmas | |
| BR112017004510A2 (pt) | anticorpos monoclonais isolados; anticorpos monoclonais ou fragmentos de ligação a antígenos do mesmo; composição; moléculas polinucleotídicas isoladas; polipeptídeo recombinante; polipeptídeos; célula hospedeira; método de fabricação de um anticorpo; uso de um agente para o tratamento de câncer em um paciente; usos de anticorpo monoclonal ou fragmento de ligação a antígenos do mesmo para o tratamento de um sujeito que sofre de um câncer; uso de anticorpo monoclonal para o tratamento de um sujeito que sofre de um câncer; composição compreendendo um anticorpo de ligação a agr2; composição compreendendo um anticorpo de ligação a c4.4a; composição compreendendo um anticorpo de ligação a agr2 e um anticorpo de ligação a c4.4a; composição compreendendo um anticorpo; uso de um anticorpo de ligação a agr2; uso de um anticorpo de ligação a c4.4a; uso de um anticorpo; e kit compreendendo um anticorpo | |
| MX2018013222A (es) | Anticuerpos de interferon beta y usos de los mismos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |